Durvalumab vs Gemifloxacin Mesylate

## Durvalumab vs Gemifloxacin Mesylate: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Gemifloxacin Mesylate**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Gemifloxacin Mesylate — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Gemifloxacin Mesylate — Small molecule.